Rodney Turner assumed duties as CEO of AYOXXA in October 2016. Prior to this, he was an independent board member. With almost ten years of experience as senior Corporate Development executive with Life Technologies, he has excelled as a senior business development executive, contributing to the growth of numerous biotech startups in the US and Germany over the past 20 years.

Having served on our Supervisory Board for two years, Wolfgang Kintzel joined AYOXXA as COO to lead our global commercial and marketing efforts. He is a senior management professional with over 20 years of experience in various executive positions within pharmaceutical, medical device, and biotechnology companies. After the successful exit of amaxa Biosystems in 2008, Wolfgang chaperoned the development of several startups as board member, advisor, CEO and Head of the Life Sciences Venture Capital team at NRW.BANK.

Markus Zumbansen drives our product development with more than 15 years of experience designing, planning, and building platform technologies consisting of a device, consumables, and biochemical reagents. After receiving his PhD in Biochemistry from the University of Cologne for research in neurobiology and signal transduction, he held different R&D positions at amaxa Biosystems (now Lonza) and Miltenyi Biotec.

Andreas Richter joined the AYOXXA management team in January 2015, bringing expertise and knowledge from 20 years in the banking industry, in consulting, and as CFO of life sciences companies like Direvo Biotech and 4-Antibody. His track record includes several successful financial rounds and M&A transactions for growth companies. Andreas studied Business Administration at the University of Cologne and at Penn State University.